Advocacy intelligence hub — real-time data for patient organizations
BOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
BOSENTAN: New indication approved
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Foundation grants
Copay cards
Travel grants
Foundation Grants7
PAN Foundation — Pulmonary arterial hypertension
PAN Foundation
NORD Patient Assistance — Pulmonary arterial hypertension
NORD Patient Assistance
Good Days — Pulmonary arterial hypertension
Good Days
HealthWell Foundation — Pulmonary arterial hypertension
HealthWell Foundation
The Assistance Fund — Pulmonary arterial hypertension
The Assistance Fund
Patient Advocate Foundation — Pulmonary arterial hypertension
Patient Advocate Foundation
Patient Services Inc — Pulmonary arterial hypertension
Patient Services Inc
Copay Assistance13
Treprostinil
United Therapeutics
Ambrisentan
Gilead
Ventavis
CoTherix, Inc.
TADALAFIL
Eli Lilly
Sterile Diluent For Treprostinil
Dr.Reddy's Laboratories Inc.,
Uptravi
Janssen
Epoprostenol
GlaxoSmithKline
SILDENAFIL CITRATE
Pfizer
TYVASO
United Therapeutics
Sildenafil
Pfizer
Tyvaso DPI
United Therapeutics
FLOLAN
GlaxoSmithKline
OPSYNVI
Janssen
Travel Grants6
GSK for You Patient Assistance Program
GSK
ONWARD Patient Support Program
UCB
Opsumit Patient Assistance Enrollment Form
PAN Foundation Pulmonary Hypertension Copay Grant
PAN Foundation
QuickRx Specialty Pharmacy Tyvaso Copay Assistance
QuickRx Specialty Pharmacy
Tyvaso Patient Assistance Program
Opsynvi
(MACITENTAN AND TADALAFIL)Orphan drugActelion Pharmaceuticals US, Inc.
Endothelin Receptor Antagonist [EPC]
12.1 Mechanism of Action Macitentan Endothelin (ET)-1 and its receptors (ETA and ETB) mediate a variety of deleterious effects, such as vasoconstricti...
Tyvaso DPI
(treprostinil inhalation powder)Orphan drugUnited Therapeutics Corporation
Prostacycline Vasodilator [EPC]
12.1 Mechanism of Action Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary...
Uptravi
(selexipag)Orphan drugJanssen
Prostacyclin Receptor Agonist [EPC]
12.1 Mechanism of Action Selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin. Selexipag is hydr...
Opsumit
(macitentan)Orphan drugJanssen
Endothelin Receptor Antagonist [EPC]
12.1 Mechanism of Action Endothelin (ET)-1 and its receptors (ET A and ET B ) mediate a variety of deleterious effects, such as vasoconstriction, fibr...
Tyvaso
(treprostinil)Orphan drugUnited Therapeutics
Prostacycline Vasodilator [EPC]
12.1 Mechanism of Action Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary...
Tadalafil
(TADALAFIL)Orphan drugNorthwind Health Company, LLC
Phosphodiesterase 5 Inhibitor [EPC]
12.1 Mechanism of Action Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine ...
Ambrisentan
(AMBRISENTAN)Orphan drugCipla USA Inc.
Endothelin Receptor Antagonist [EPC]
12.1 Mechanism of Action Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ET A and ET B , mediate the effects o...
Ventavis
(Iloprost inhalation solution)Orphan drugCoTherix, Inc.
First longitudinal spatial transcriptomics analysis in pulmonary arterial hypertension.
First longitudinal spatial transcriptomics analysis in pulmonary arterial hypertension.
Evaluating sotatercept in the treatment of pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling, right ventricular overload, and premature death. Despite advances achieved through endoth...
Update on pulmonary hypertension.
The hemodynamic definition of pulmonary hypertension including a mean pulmonary arterial pressure > 20 mmHg is evidence based, but the threshold of 15 mmHg for the pulmonary...
Targeting the Hippo pathway in pulmonary arterial hypertension: emerging pharmacological strategies.
Pulmonary arterial hypertension (PAH) is a severe, progressive disease characterized by pulmonary vascular remodeling and increased resistance, ultimately leading to right heart failure and high morta...
Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions.
Pulmonary hypertension (PH) associated with left heart disease (LHD) is the most prevalent form of PH and is associated with substantial morbidity and mortality risk. Diagnosis is challenging because ...
EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.
Pulmonary arterial hypertension (PAH) is a progressive condition marked by the abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs), leading to significant remodelling of the pulmon...
Liang Zhong, PhD
National Heart Centre Singapore
Richard Aranda
Gossamer Bio Inc.
G. Ganesh Konduri, MD
Medical College of Wisconsin
Corey E Ventetuolo, MD, MS, M.D
Brown University
📍 RIVERSIDE, RI
Andrew Boyle, MD
Wake Forest University Health Sciences
Silvia Ulrich, Prof.
University of Zurich